|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
New Published Data Demonstrate Endocyte, Inc. (ECYT)'s Targeted Small Molecule Drug Conjugate Approach Shows Promising Results in Polycystic Kidney Disease Model
8/3/2012 9:26:54 AM
WEST LAFAYETTE, Ind., Aug. 3, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Endocyte's approach of utilizing a SMDC targeted to the folate receptor (FR) may provide a promising treatment for patients with autosomal-dominant polycystic kidney disease (ADPKD). In a mouse model of polycystic kidney disease (PKD), treatment with a folate-conjugated form of rapamycin, FC-rapa, (EC0371) strongly attenuated proliferation and growth of renal cysts and preserved renal function. The results were published online ahead of print in the Journal of the American Society of Nephrology and will be available in print in the October issue.
|
|
|
|
|
|
|
|
|
|
|